Abstract
The histopathology of multiple sclerosis (MS) is characterized by focal inflammation, demyelination, loss of oligodendrocytes, reactive astrogliosis, and axonal pathology. Of these hallmarks, myelin loss has attracted most interest, and MS research has historically focused on mechanisms associated with inflammatory demyelination and remyelination. Although the neuropathology of MS is primarily demyelinating, a number of reports describe axonal injury in the disease [1-9]. In fact, axonal pathology in MS lesions was described more than a century ago [10]. Charcot (1868), for example, discussed MS lesions in terms of demyelination and astrogliosis, but he also mentioned axonal loss [11]. Current data on axonal pathology in MS have been provided through a variety of approaches, including magnetic resonance imaging (MRI) [7, 12-14], magnetic resonance spectroscopy (MRS) [2, 3, 5, 15] and morphological analysis of brain sections [4, 9]. Immunohistochemical studies have recently emphasized the correlation between inflammation and axonal damage during the early stages of MS [4, 9]. In addition, long-term axonal pathology has been described in a number of myelin protein gene knockout and trans-genic mice models [6, 8, 16], as well as in chronic MS patients [17, 18], indicating that lack of myelin-related molecules can result in axonal pathology. Together, these data suggest that cumulative axonal degeneration constitutes a significant pathogenic component of MS, and indicate that loss of axons may be a main determinant of the progressive neurological disability seen in these patients [1, 3, 5, 6, 8, 17].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bjartmar C, Trapp BD (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 14:271–278
Arnold DL et al (1994) Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 36:76–82
De Stefano N et al (1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121:1469–1477
Trapp BD et al (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278–285
Matthews PM et al (1998) Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol 18:327–336
Bjartmar C, Yin X, Trapp BD (1999) Axonal pathology in myelin disorders. J Neurocytol 28:383–395
van Waesberghe JHTM et al (1999) Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 46:747–754
Trapp BD, Ransohoff RM, Fisher E, Rudick RA (1999) Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 5:48–57
Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393–399
Kornek B, Lassman H (1999) Axonal pathology in multiple sclerosis. A historical note. Brain Pathol 9:651–656
Charcot M (1868) Histologie de le sclerose en plaques. Gazette Hopitaux 141:554–558
Davie CA et al (1995) Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 118:1583–1592
Losseff NA et al (1996) Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119:701–708
Losseff NA et al (1996) Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119:2009–2019
Narayana PA, Doyle TJ, Dejian L, Wolinsky JS (1998) Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 43:56–71
Scherer S (1999) Axonal pathology in demyelinating diseases. Ann Neurol 45:6–7
Bjartmar C et al (2000) Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl-aspartate in chronic multiple sclerosis patients. Ann Neurol 48:893–901
Lovas G et al (2000) Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 123:308–317
Koo EH et al (1990) Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Nat Acad Sci USA 87:1561–1565
Hohlfeld R (1997) Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120:865–916
Bell JI, Lathrop GM (1996) Multiple loci for multiple sclerosis. Nature Genet 13:377–378
Ebers GC, Dyment DA (1998) Genetics of multiple sclerosis. Semin Neurol 18:295–299
Noseworthy JH, Luccinetti C, Rodriquez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343:938–952
Rivera-Quinones C et al (1998) Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nat Med 4:187–193
Njenga MK et al (1999) Absence of spontaneous central nervous system remyelination in class II-deficient mice infected with Theiler’s virus. J Neuropathol Exp Neurol 58:78–91
Giese KP et al (1992) Mouse PO gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. Cell 71:565–576
Anzini P et al (1997) Structural abnormalities and deficient maintenance of peripheral nerve myelin in mice lacking the gap junction protein connexin 32. J Neurosci 17:4545–4551
Yin X et al (1998) Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci 18:1953–1962
Griffiths I et al (1998) Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 280:1610–1613
Sahenk Z, Chen L, Mendell JR (1999) Effects of PMP22 duplication and deletions on the axonal cytoskeleton. Ann Neurol 45:16–24
Ganter P, Prince C, Esiri MM (1999) Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol Appl Neurobiol 25:459–467
Evangelou N et al (2000) Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 47:391–395
Stevenson VL, Miller DH (1999) Magnetic resonance imaging in the monitoring of disease progression in multiple sclerosis. Multiple Sclerosis 5:268–272
Kidd D et al (1993) Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 43:2632–2637
Filippi M et al (1997) A longitudinal magnetic resonance imaging study of the cervical cord in multiple sclerosis. J Neuroimaging 7:78–80
Brownell B, Hughes JT (1962) The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry 25:315–320
Simon JH et al (1999) A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 53:139–148
Rudick RA et al (1999) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53:1698–1704
Lumsden CE (1970) The neuropathology of multiple sclerosis. In: Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology, vol 9. North-Holland, Amsterdam, pp 217–309
Kidd D et al (1999) Cortical lesions in multiple sclerosis. Brain 122:17–26
van Walderveen MAA et al (1998) Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 50:1282–1288
Brück W et al (1997) Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 42:783–793
Baslow MH (2000) Functions of N-acetyl-L-aspartate and N-acetyl-L-aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling. J Neurochem 75:453–459
Moffett JR, Namboodiri MAA, Cangro CB, Neale JH (1991) Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 2:131–134
Simmons ML, Frondoza CG, Coyle JT (1991) Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45:37–45
Patel TB, Clark JB (1979) Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and involvement in mitochondrial/cytosolic carbon transport. Biochem J 184:539–546
Truckenmiller ME, Namboodiri MAA, Brownstein MJ, Neale JH (1985) N-acetylation of L-aspartate in the nervous system: differential distribution of a specific enzyme. J Neurochem 45:1658–1662
Clarke DD et al (1975) A relationship of N-acetylaspartate biosynthesis to neuronal protein synthesis. J Neurochem 24:479–485
Cangro CB et al (1987) Immunohistochemistry and biosynthesis of N-acetylaspartylglutamate in spinal sensory ganglia. J Neurochem 49:1579–1588
Lee JH, Arcinue E, Ross BD (1994) Brief report: organic osmolytes in the brain of an infant with hypernatremia. N Engl J Med 331:439–442
Graham GD et al (1992) Proton magnetic resonance spectroscopy of cerebral lactate and other metabolites in stroke patients. Stroke 23:333–340
Pioro E, Antel JP, Cashman NR, Arnold DL (1994) Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 44:1933–1938
Davie CA et al (1994) Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 117:49–58
Matthews PM et al (1996) Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 119:715–722
Narayanan S et al (1997) Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 41:385–391
Fu L et al (1998) Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 121:103–113
Lee MA et al (2000) Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. Arch Neurol 57:65–70
De Stefano N, Matthews PM, Arnold DL (1995) Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 34:721–727
Rango M et al (1995) Central nervous system trans-synaptic effects of acute axonal injury: a1H magnetic resonance spectroscopy study. Magn Reson Med 33:595–600
de Waegh SM, Lee VM-Y, Brady ST (1992) Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell 68:451–463
Clark JB (1998) N-Acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci 20:271–276
Saragea M et al (1965) Biochemical changes occurring in animals with experimental allergic encephalomyelitis. Med Pharmacol Exp 13:74–80
Brenner RE et al (1993) The proton NMR spectrum in acute EAE: the significance of the change in the Cho:Cr ratio. Magn Reson Med 29:737–745
Rudick RA, Goodman A, Herndon RM, Panitch HS (1999) Selecting relapsing remitting multiple sclerosis patients for treatment: the case for early treatment. J Neuroimmunol 98:22–28
Mews I et al (1998) Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Multiple Sclerosis 4:55–62
Reddy H et al (2000) Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain 123:2314–2320
Foster RE, Whalen CC, Waxman SG (1980) Reorganization of the axon membrane in demyelinated peripheral nerve fibers: morphological evidence. Science 210:661–663
Felts PA, Baker TA, Smith KJ (1997) Conduction in segmentally demyelinated mammalian central axons. J Neurosci 17:7267–7277
Waxman SG (1998) Demyelinating diseases - new pathological insights, new therapeutic targets. N Engl J Med 338:223–225
Gonen O et al (2000) Total brain N-acetylaspartate. A new measure of disease load in MS. Neurology 54:15–19
Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430–1438
McFarland HF et al (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 32:758–766
Rudick RA et al (1997) Management of multiple sclerosis. N Engl J Med 337:1604–1611
Trapp BD, Ransohoff R, Rudick R (1999) Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 12:295–302
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Italia
About this chapter
Cite this chapter
Bjartmar, C., Trapp, B.D. (2004). Neuropathology and Disease Progression in Multiple Sclerosis. In: Hommes, O.R., Comi, G. (eds) Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis. Topics in Neuroscience. Springer, Milano. https://doi.org/10.1007/978-88-470-2117-4_5
Download citation
DOI: https://doi.org/10.1007/978-88-470-2117-4_5
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2171-6
Online ISBN: 978-88-470-2117-4
eBook Packages: Springer Book Archive